Health-care companies rose as optimism about a boom in obesity drugs regained momentum.

Novo Nordisk shares ticked up after the maker of obesity injection Wegovy unveiled a research project aimed at adding up to two more obesity treatments to its large pipeline, which already includes a long list of experimental obesity drugs being tested in clinical trials.

Takeda Pharmaceutical reported a fourth-quarter loss and forecast a drop in annual net profit due partly to restructuring expenses.

Embecta shares were rose after the drugmaker boosted its projection for growth in fiscal year 2024.

Write to Rob Curran at

(END) Dow Jones Newswires

05-09-24 1726ET